Related Experiment Video
Updated: Mar 7, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?
Antonio Di Biagio1, Marta Ameri2, Davide Sirello1
1Infectious Disease Clinic, IRCCS San Martino - IST Hospital, Genoa, Italy.
Insights
Routine CD4+ cell count monitoring for stable HIV-1 patients on cART has limited clinical relevance. Annual monitoring is recommended, potentially saving 33-67% in healthcare costs.
Area of Science:
- Immunology
- Infectious Diseases
- Public Health
Background:
- CD4+ cell count is crucial for HIV staging and treatment decisions.
- Quarterly monitoring in stable patients on cART shows limited clinical utility.
- This study evaluates the necessity of frequent CD4+ monitoring in stable HIV-1 patients.
Purpose of the Study:
- To assess the clinical relevance of quarterly CD4+ cell counts in stable HIV-1 patients on cART.
- To identify factors associated with CD4+ count decline below 350 cells/mm³.
- To forecast potential cost savings from reduced CD4+ monitoring.
Main Methods:
- Analysis of data from HIV-infected patients (>18 years) in Genoa, Italy.
- Kaplan-Meier estimates and confidence intervals to assess CD4+ count probability.
- Multivariate Cox and logistic regression to identify factors for CD4+ falls.
Main Results:
- Stable patients have >98% probability of maintaining CD4+ >350 cells/mm³.
- HCV co-infection and high HIV-RNA levels are associated with CD4+ falls.
- Cost savings from reduced monitoring range from 33% to 67%.
Conclusions:
- Stable HIV-1 patients are unlikely to experience CD4+ <350 cells/mm³ within a year.
- Annual CD4+ monitoring is recommended for stable HIV-1 patients.
- Reducing monitoring frequency can lead to significant cost savings.
Background:
In the last 20 years routine T CD4+ lymphocyte (CD4+) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4+ cell count monitoring results in limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4+ cell counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be achieved by reducing CD4+ monitoring in such a category of patients.
Methods:
The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two large infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4+ cell counts dropping below a threshold value set at 350 cells/mm3 is assessed using confidence intervals and Kaplan-Meier survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify factors associated with CD4+ cell count falls below 350 cells/mm3.
Results:
Statistical analysis reveals that among stable patients the probability of maintaining CD4+ >350 cell/mm3 is more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous examinations are associated with CD4+ falls below 350 cells/mm3. Moreover, results suggest that the cost saving that could be obtained by reducing CD4+ examinations ranges from 33 to 67%.
Conclusions:
Empirical findings shows that patients defined as stable at enrollment are highly unlikely to experience a CD4+ value <350 cell/mm3 in the space/arc of a year. The research supports a recommendation for annual CD4+ monitoring in stable HIV-1 patients.
